Bahl & Gaynor Inc’s Eli Lilly & Co Position
Does Bahl & Gaynor Inc own Eli Lilly & Co (LLY)? Yes — 666.1K shares worth $613M (+3.09% of its 13F portfolio) as of Q1 2026, down from 787.4K shares the prior filed quarter.
Position Value
$613M
Q1 2026
Shares
666.1K
% of Portfolio
+3.09%
Quarters Held
30
currently held
Position History LLY
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 666.1K | $613M | +3.09% |
| Q4 2025 | 787.4K | $846M | +4.28% |
| Q3 2025 | 804.0K | $613M | +3.05% |
| Q2 2025 | 831.5K | $648M | +3.28% |
| Q1 2025 | 844.4K | $697M | +3.55% |
| Q4 2024 | 851.9K | $658M | +3.48% |
| Q3 2024 | 863.6K | $765M | +3.94% |
| Q2 2024 | 865.4K | $783M | +4.38% |
| Q1 2024 | 877.8K | $683M | +3.80% |
| Q4 2023 | 896.6K | $523M | +3.14% |
| Q3 2023 | 935.1K | $502M | +3.21% |
| Q2 2023 | 963.1K | $452M | +2.75% |
| Q1 2023 | 1.11M | $381M | +2.05% |
| Q4 2022 | 978.5K | $358M | +2.24% |
| Q3 2022 | 1.05M | $339M | +2.24% |
| Q2 2022 | 983.7K | $319M | +2.10% |
| Q1 2022 | 868.0K | $249M | +1.83% |
| Q4 2021 | 1.19M | $328M | +1.83% |
| Q3 2021 | 1.22M | $281M | +1.72% |
| Q2 2021 | 1.19M | $273M | +1.66% |
| Q1 2021 | 1.16M | $216M | +1.37% |
| Q4 2020 | 1.15M | $194M | +1.24% |
| Q3 2020 | 1.10M | $163M | +1.15% |
| Q2 2020 | 1.11M | $182M | +1.37% |
| Q1 2020 | 1.08M | $150M | +1.30% |
| Q4 2019 | 1.01M | $132M | +0.92% |
| Q3 2019 | 736.6K | $82M | +0.60% |
| Q2 2019 | 884.7K | $98M | +0.73% |
| Q1 2019 | 670.0K | $87M | +0.80% |
| Q4 2018 | 598.3K | $69M | +0.74% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Bahl & Gaynor Inc’s full portfolio or all institutional holders of LLY.